

CareDx at ESOT 2023: Leading the Way in Innovative Transplant Research

Patrick G., Kidney transplant recipient

AlloSeq cfDNA: 11 Accepted Abstracts

Type Title Presenter Session

Scientific abstracts featuring AlloSeq cfDNA

Kidney Poster The EVACADE study: dd-cfDNA for diagnosis of acute rejection in kidney F. Boix (P158) transplantation on behalf of the Spanish Working Group on Transplant Immunology Poster Donor-derived cell-free DNA identifies "troubled" kidney allografts E. Gonzalez (P433) Poster Assessment of dd-cfDNA in kidney transplantation as a marker of graft injury -J. Silvano (P169) a prospective study Full Oral Assessment of donor-derived cell-free DNA (dd-cfDNA) in kidney transplant 20/09/2023, (OS11_1) Best of ESOT 2023 Benning 10.00 recipients with indication biopsy Impact of donor-derived cell-free DNA assessment in monitoring kidney transplant 20/09/2023 Brief Oral A. Pagliazzi recipients: interim report of a prospective longitudinal study 10.00 Heart 18/09/2023, Initial experience with local laboratory run assay to detect donor-derived cell-free DNA Moderated ePoster S. Manno for non-invasive diagnosis of acute myocardial rejection 14.15 Moderated ePoster Local laboratory-run donor-derived cell-free DNA testing in stable heart 18/09/2023. T. Teszák (MPS1 6) transplantation: two-centre european feasibility study 14.15 Lung Brief Oral Clinical relevance of cell-free DNA quantification and qualification during the first 19/09/2023, S. Casas (BOS6 4) month after lung transplantation 10.18 Brief Oral (BOS6_5) ESOT Award 2023 Comparison of plasma donor-derived cell-free DNA with LASHA scoring system in 19/09/2023, F. Pezzuto lung transplantation: a single centre experience 10.24 Multi-Centric Study Poster Multi-centric analytical performance validation of an IVD assay to quantify T. Viard (P033) donor-derived cell-free DNA for solid organ transplant surveillance

Scientific abstracts featuring AlloSeq cfDNA and iBox

Kidney			
Focus Group (FG3_1)	Evolution of dd-cfDNA during the first week after surgery predicts medium to long-term renal outcomes	D. Cucchiari	19/09/2023, 08.00

AlloSeq cfDNA is CE/IVD and Research Use Only. For local regulatory status, please contact CareDx. Research Use Only products are not to be used for diagnostic procedures. AlloSeq cfDNA is not available within the US. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries. AlloSeq is a registered trademark with the US Patent and Trademark Office. © 2023 CareDx, Inc. All service marks or trademarks are owned or licensed by CareDx, Inc. or its stillates. All rights reserved.